Sekar Kathiresan - Dec 22, 2021 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role: Chief Executive Officer, Director
Signature: /s/ Andrew Ashe, as Attorney-in-Fact for Sekar Kathiresan
Stock symbol: VERV
Transactions as of: Dec 22, 2021
Transactions value $: -$4,322,144
Form type: 4
Date filed: 12/27/2021, 05:08 PM
Previous filing: Jun 21, 2021
Next filing: Dec 29, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VERV	Common Stock	Options Exercise	$79.2K	+57K	+14.02%	$1.39^*	464K	Dec 22, 2021	Direct
transaction	VERV	Common Stock	Sale	-$220K	-5.87K	-1.27%	$37.38	458K	Dec 22, 2021	Direct	F1, F2
transaction	VERV	Common Stock	Sale	-$641K	-16.7K	-3.65%	$38.31	441K	Dec 22, 2021	Direct	F1, F3
transaction	VERV	Common Stock	Sale	-$1.22M	-31.1K	-7.06%	$39.06	410K	Dec 22, 2021	Direct	F1, F4
transaction	VERV	Common Stock	Sale	-$130K	-3.27K	-0.8%	$39.78	407K	Dec 22, 2021	Direct	F1, F5
transaction	VERV	Common Stock	Options Exercise	$79.2K	+57K	+14.02%	$1.39^*	464K	Dec 23, 2021	Direct
transaction	VERV	Common Stock	Sale	-$2.27M	-57K	-12.3%	$39.90	407K	Dec 23, 2021	Direct	F1
holding	VERV	Common Stock						81K	Dec 22, 2021	Kathiresan Family 2021 Irrevocable Trust
holding	VERV	Common Stock						81K	Dec 22, 2021	Sekar Kathiresan 2021 Irrevocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VERV	Stock Option (right to buy)	Options Exercise	$0	-57K	-13.19%	$0.00	375K	Dec 22, 2021	Common Stock	57K	$1.39	Direct	F6
transaction	VERV	Stock Option (right to buy)	Options Exercise	$0	-57K	-15.2%	$0.00	318K	Dec 23, 2021	Common Stock	57K	$1.39	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2021.
F2	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.84 to $37.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) of this Form 4.
F3	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.81 to $38.76, inclusive.
F4	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.77 to $39.70, inclusive.
F5	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.74 to $39.98, inclusive.
F6	The remaining shares underlying this option, which was granted on April 15, 2019 and commenced vesting on July 22, 2019, vest in equal monthly installments thereafter until July 22, 2023.